Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
FunnyGuy, from the latest RNS: "The Board of Directors remains confident that the Company is on course to deliver topline Phase 1a results in Q2 2024". Your contention that "results soon will show a very disappointing outcome" is, at best, mischievous, at worst, downright misleading. If the BoD remains confident, I think I'll take their word on that. Financing, of course, remains a concern, granted.
...consolidation was announced, to the involvement of Peel Hunt, to the financing deal with Riverfort, to the crazy spreads, to the 2.5p incremental falls in the sp (even today) - I should have paid attention to my gut feeling. Never again. An expensive lesson. Someone mentioned Deepmatter. Exactly my thoughts today. We must fight this tooth and nail now.
From yesterday's RNS: "The Company is in discussions to assess alternative funding arrangements". If they are "assessing" alternative funding arrangements, does that mean there are offers already on the table, and these offers are being discussed? It's all a bit shambolic to be honest. All I keep thinking is that in March 2020 the sp stood at 0.25p (12.5p new money). We are still higher today (just), although I know this is scant consolation for most. I just think Sareum is so much further ahead today than it was in 2020, yet the sp is languishing at near the March 2020 levels. Anyone buying in today is surely getting the bargain of a lifetime, or am I completely barking?
Before we start ousting board members, who on earth advised them to go the RF route? If it was PH, their association with SAR has been an unmitigated disaster, so my preference would be to sack them first (or whoever brokered the RF deal). I do feel the pain of many here, but we do know the data have been sound so far, and the volumes have been relatively thin (or at least not enough to warrant the ridiculous drops). My bugbear has been the advertised spreads between the bid and the ask, which is surely deterring new buyers. Why do we drop in 2.5p/5p increments? It would appear excessive given the volumes traded, unless of course someone doesn't want you to buy?
SOG, the wording of the recent RNS ("the CRT Pioneer Fund has entered into a development and commercialization license agreement for SRA737 with a PRIVATE biopharma company based in the United States") would seem to rule out MEI Pharma surely? But what about Allorion Therapeutics? It fits the profile...
https://alloriontx.com
https://www.prnewswire.com/news-releases/allorion-therapeutics-a-next-generation-precision-medicine-company-focusing-on-oncology-and-autoimmune-diseases-raises-50-million-series-b-financing-301767570.html
A quick question. Are the directors allowed to buy if there is a NDA in place? It might explain the radio silence on their part. And for those despairing, a personal anecdote. I was, in March 2020, 70% down on my holding here. I then went to 1000% up (by July 2021), and am now 30% down! Things can change here, and quite rapidly. But having an exit strategy is always a good idea. Trust me!
Top of the share risers board yesterday (for a while, at least), and now top of the share fallers today, on volume of around 150,000 shares (or roughly 0.2% of shares in issue). Go figure...
The whole "subject to financing" concern is real, but should not be overstated. I remember reading something similar many times in previous RNSs. So I decided to check, and the first one I checked (from August 2021), I found this: "The Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022, subject to successful completion of the ongoing preclinical toxicology studies, gaining the requisite approval and financing." I'm quite sure there are other examples from even before 2021. The RF deal is, admittedly, a shocker but somehow Sareum continues to stay afloat. And not only that, it continues to impress in clinical trials, as per yesterday's RNS. Patience, as ever, is the key here.
Sorry, Darien, forgive me, but were you calling 0.8p back in March 2022? All I can find in your post history is you saying in December 2020 that the Sar sp would be back to 1p "in a month". It actually went on to reach 9p by August 2021! Also, in the last 30 days, you have posted only once on the Sar bb - today - presumably just to stick the boot in? You seem to be familiar with snake oil salesmen, though...
Just wondering why the BoD are not buying at these bargain basement prices? I mean, Sareum is in a much better position now than when the SP last saw these lows (0.8p in old money).
But isn't it the science that will determine Sareum's future? You either believe in it, or not. I think it should be "trust the scientists" and Tim and John (I believe) are leaders in their field. The current SP equates to roughly 0.9p in old money - my original average. It then 10 bagged from there. The real question is, can lightning strike twice?
High-end watch prices (for Rolex, PP, AP, for example) seem to be stabilizing, so there's some hope WOSG has seen the worst. Rolex acquiring Bucherer might pose a more systemic risk to WOSG, however. Not really sure. One thing I'm hearing is some new watches are now appearing 'under list' on the grey market, and some less desirable brands are even being offered at a discount to their retail price at ADs (including Omega, Breitling, etc.).
So, yesterday's drop was to accommodate PH's mates then? Seen it all before. Hope no one was spooked into selling...
Its likely promotion to the FTSE 250 should attract the interest of portfolio managers. As I said before, this rise has legs. Hold.
Then why, at the time, did Dr Reader state: "The results from our Covid-19 research project are very encouraging and provide clear evidence of the potential of SDC-1801 to reduce the excessive inflammatory response seen in severe Covid-19. We are keen to progress this project to the next stage and will now explore our options to find the best way to fund these next steps. This could include the UK government's AGILE clinical development platform, which was established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development plan targeting autoimmune diseases. We look forward to providing updates on our progress as we reach key milestones in the development of SDC-1801."? I feel that we were misled on AGILE, and on the "orderly queue" comment (whether off the cuff, or not). Both statements caused the share price to spike, but in the end led to nought. I think shareholders deserve better, is all I'm saying.
Spondulicks, that all sounds plausible, until we cast our minds back to 2020, and the "pressing need for urgent treatments" at that time. https://www.lse.co.uk/rns/SAR/notification-of-grant-award-for-covid-19-research-4faw31mw6ncledl.html
As you will see, Sareum were awarded a grant of "£174,000 ...(the 'Grant') by UK Research & Innovation ('UKRI') to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in severe phase Covid-19". This was great news, especially for the share price. Then, in July 2021, we were told that the "completed Covid-19 research project had delivered encouraging results". https://www.lse.co.uk/rns/SAR/covid-19-research-project-results-j5q89njlqb68nqx.html "The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor." Wow, I hear you say. There was also talk (from Dr Reader) of joining the AGILE program, established to fast forward into clinical trials precisely the sort of potential treatment that had shown such promise in their preliminary findings. The share price responded accordingly, in tandem with the HNWI investments. Then, nothing. Zilch. Nada. What happened? Talk about dropping the ball! The share price went the same way as the ball. Then, of course, Dr Parker tried to reassure us with the "form an orderly queue" comment (re: SRA 737) which helped the share price recover somewhat (from 70p to 140p over a relatively short period). Again, what happened? And then came RF (an awful solution to a glaring funding issue), which brings us to now. I'm not for changing the board. But, at the same time, I don't particularly like being misled. So, Spondulicks, whilst I echo your comments regarding the pressing need for a potential treatment for the latest bad news coming out of China, do you seriously think our board are capable of riding to the rescue? I would love to believe so, but past history doesn't really inspire confidence.
Fanti, you think increasing our interest in SRA737 to 50%, thereby actively "controlling, marketing, and commercializing the asset" is realistic? Therein lies the problem, I'm afraid. The science seems robust, but the business acumen would appear non-existent. Dr Parker claimed at last year's AGM that it was a case of "form an orderly queue" when it came to active interest in SRA737. So what happened?
Bushy, for some reason (maybe Egypt's proximity to the whole Gaza mess), Centamin seems to be lagging other miners in the sector (see https://www.google.com/finance/quote/HOC:LON?hl=en&comparison=LON%3ACEY&window=1Y ). With gold near, or at, all-time highs in most currencies, one wonders what's holding Centamin back. 159p would appear a tad optimistic near term, but 120-130p should be doable when the market finally wakes up.
GDR have a similar arrangement with RF, and each time they have drawn down on their facility it has warranted an RNS. I'm not sure if it's a formal requirement or merely a heads up from the GDR board. Interestingly, their SP has similarly nosedived since RF became involved.
Https://news.sky.com/story/uk-to-rejoin-eu-horizon-programme-in-bespoke-new-agreement-12956520
I always wondered whether MHRA's refusal to authorize Sareum's CTA was connected to the fact the UK was outside of the EU, and hadn't yet figured out its own protocols for CTAs. All probably ancient history now, although might it have a positive impact on any future CTA re: SDC-1802?